Glenmark Pharma launches antidiabetic injectable
Glenmark Pharmaceuticals has launched the first biosimilar of the popular anti-diabetic drug, Liraglutide in India, which will lower the therapy cost by approximately 70%. The drug is being marketed under the brand Lirafit, following an approval from the Drug Controller General of India. It is priced around Rs 100 for a standard dose of 1.2 … Read more